Information Provided By:
Fly News Breaks for June 5, 2017
TGTX
Jun 5, 2017 | 06:56 EDT
Jefferies analyst Matthew Andrews believes the data announced over the weekend by TG Therapeutics for TG-1101 plus ibrutinib in patients with previously treated high risk Chronic Lymphocytic Leukemia are supportive of approval. The hazard ratio of 0.56 is encouraging, Andrews tells investors in a research note. He views TG shares as undervalued and keeps a Buy rating on the name with a $23 price target.
News For TGTX From the Last 2 Days
There are no results for your query TGTX
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.